| Pair Name | Oroxylin A, Cisplatin | ||
| Phytochemical Name | Oroxylin A (PubChem CID: 5320315 ) | ||
| Anticancer drug Name | Cisplatin (PubChem CID: 5702198 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Oroxylin A, Cisplatin | |||
| Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Expression | XPC | hsa7508 |
| In Vitro Model | NCI-H460 | Lung large cell carcinoma | Homo sapiens (Human) | CVCL_0459 |
| Result | Our findings not only demonstrate a crucial role of XPC dependent NER in hypoxia-induced cisplatin resistance, but also suggest a previously unrecognized tumor suppressive mechanism of Oroxylin A in NSCLC which through sensitization of cisplatin-mediated growth inhibition and apoptosis under hypoxia. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Oroxylin A reverses hypoxia-induced cisplatin resistance through inhibiting HIF-1α mediated XPC transcription. Oncogene. 2020 Nov;39(45):6893-6905. doi: 10.1038/s41388-020-01474-x. | Click |
